Olanzapine for nausea and vomiting

Area of Science:

• Palliative Care
• Pharmacology
• Neuroscience

Background:

• Nausea and vomiting (emesis) are common and distressing symptoms in palliative care.
• Current treatments often involve multiple medications due to complex receptor involvement in emesis.
• Existing therapies may not fully address the multifaceted nature of nausea and vomiting.

Purpose of the Study:

• To evaluate the potential efficacy of olanzapine in treating nausea and vomiting in palliative care patients.
• To explore olanzapine's mechanism of action in managing emesis based on its receptor-blocking properties.

Main Methods:

• Review of current research on nausea and vomiting triggers and treatments.
• Analysis of olanzapine's pharmacological profile, including its interaction with neurotransmitter receptors.
• Assessment of existing studies suggesting olanzapine's effectiveness in managing emesis.

Main Results:

• Olanzapine blocks multiple neurotransmitter receptors, including dopaminergic, serotonergic, adrenergic, histaminergic, and muscarinic receptors.
• Many of these blocked receptors are implicated in the pathophysiology of nausea and vomiting.
• Preliminary studies indicate promising results for olanzapine in controlling emesis.

Conclusions:

• Olanzapine's broad receptor antagonism presents a potential therapeutic advantage for managing complex nausea and vomiting.
• Further clinical investigation is warranted to confirm olanzapine's role in palliative care for emesis control.
• Olanzapine may offer a novel monotherapy or adjunctive treatment for refractory nausea and vomiting.